Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Trial Profile

Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Ensartinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms eXalt2; Xalt2
  • Sponsors Xcovery Holdings
  • Most Recent Events

    • 12 Mar 2018 Results evaluating safety of Ensartinib in ALK-positive Non-Small Cell Lung Cancer patients published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 05 Mar 2018 Planned number of patients changed from 150 to 190.
    • 05 Mar 2018 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top